By vgreene, 22 April, 2016 Repeat fasting lipid panel5 4-12wk after statin start (or modification), then q3-12mo
By vgreene, 22 April, 2016 If LDL–C reduction from baseline 50% reduction from baseline on high-dose statin): Shared decision-making regarding adding nonstatin7
By vgreene, 22 April, 2016 Discuss potential for risk-reduction benefits, adverse effects, drug interactions, pt preferences, etc, to inform tx decisions. If 10-yr ASCVD risk1 ≥7.5% use mod or high-intensity [A]; mod-intensity reasonable if ASCVD risk 5% to
By vgreene, 22 April, 2016 Labs: ✓ baseline fasting lipid panel,5 ✓ ALT, and if indicated ✓ CK. Eval/treat TG ≥500 mg/dL, unexplained ALT >3x ULN. Consider eval for secondary causes/conditions that may influence statin safety
By vgreene, 22 April, 2016 High-intensity statin daily dose: Atorvastatin 80 mg (or 40 mg)3 or rosuvastatin 20 mg4
By vgreene, 22 April, 2016 Mod-intensity statin daily dose:2 Atorvastatin 10 mg, fluvastatin 80 mg (as 40 mg bid), lovastatin 40 mg, pravastatin 40 mg, rosuvastatin 10 mg, simvastatin 20-40 mg
By vgreene, 22 April, 2016 Repeat fasting lipid panel6 4-12wk after statin start (or modification), then q3-12 mo
By vgreene, 22 April, 2016 If LDL–C reduction from baseline is ≥50% (for ASCVD risk ≥7.5%) or >30%-49% (for ASCVD risk